This is 'the most important decision' the FDA will make in 2020, says analyst
December 27, 2019 at 16:05 PM EST
The FDA's call on whether to approve Biogen's experimental Alzheimer's drug, aducanumab, will be the "most important decision" it will make in 2020, Bernstein analyst Ronny Gal says.
